OncoLize
Business Model
Business Model
Our business model is straight forward for the coming 5 years.
We invest to develop a series of products in-house, to take into clinical trials, with or without partners.
Our products are based on a focused and versatile selection of generic Chemo-drugs. These drugs are well-established for multiple tumor indications. Beter still, they are affordable, readily available and largely free to operate within our patent-protected ChemoGellTM- platform.
Once proven valuable, we license out these products to Oncology marketeers.
We will pick-up projects with paying Pharma customers. They may be looking to improve the delivery of their novel drugs, including Immune-modulating drugs. This provides non-dilutive funding for steps we need to take anyway with our own products. These customers can get a license to the ChemoGellTM platform and expanding IP and patents portfolio.
We pledge to work with NGO’s offering access and affordable solutions for endemic tumor diseases like liver-, lung- and cervical cancer in Low-Income Countries. This way we generate additional non-dilutive funding. These projects are managed separately under guidance by the NGO's.
Partnerships
Next to our own product development, we are open to collaborate as and enabling technology provider to your projects. These can include:
- reformulating novel drug candidates to improve solubility, stability, delivery and overall performance
- feasibility studies or advanced product development in oncology applications
- Improving the cost-performance of Immune-modulating drugs
- Developing combinations between novel drug entity and our chemo-based products
OncoLize has the exclusive worldwide licenses to the ChemoGellTM-platform.
Please use the Contact page for your enquiries
